Evidence map›Paper›PMID 37221625›Full record

ArticleExperimental hematology & oncology2023

ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer.

Shiyong Xin, Xiang Liu, Ziyao Li, Xianchao Sun, Rong Wang, Zhenhua Zhang, Xinwei Feng, Liang Jin, Weiyi Li, Chaozhi Tang and 6 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Experimental hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Shiyong Xin *Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No.150, Ji-mo Rd, Pu-dong new District, Shanghai, 200120, China.
Xiang Liu *Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No.150, Ji-mo Rd, Pu-dong new District, Shanghai, 200120, China.
Ziyao LiDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No.150, Ji-mo Rd, Pu-dong new District, Shanghai, 200120, China.
Xianchao SunDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No.150, Ji-mo Rd, Pu-dong new District, Shanghai, 200120, China.
Rong WangSchool of Pharmacy, Inner Mongolia Medical University, Hohhot, 010000, China.
Zhenhua ZhangSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
Xinwei FengSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.
Liang JinDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No.150, Ji-mo Rd, Pu-dong new District, Shanghai, 200120, China.
Weiyi LiDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No.150, Ji-mo Rd, Pu-dong new District, Shanghai, 200120, China.
Chaozhi TangDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No.150, Ji-mo Rd, Pu-dong new District, Shanghai, 200120, China.
Wangli MeiDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No.150, Ji-mo Rd, Pu-dong new District, Shanghai, 200120, China.
Qiong CaoDepartment of Pathology, The Third Affiliated Hospital of Henan University of Science and Technology, Henan, 471003, China.
Haojie WangDepartment of Central Laboratory, Zhengzhou University, Luoyang Central Hospital, Luoyang, 471003, China.
Jianguo ZhangDepartment of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Lijin FengDepartment of Pathology, Jing'an District Zhabei Central Hospital, No.619, Zhonghuaxin Road, Shanghai, 200070, China. fenglijin_2049@tongji.edu.cn.
Lin YeDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No.150, Ji-mo Rd, Pu-dong new District, Shanghai, 200120, China. doctyelin@126.com.
Shanghai East Hospital · CNSun Yat-sen University · CNFirst Affiliated Hospital of Henan University of Science and Technology · CNHenan University of Science and Technology · CNInner Mongolia Medical University · CNLuoyang Central Hospital Affiliated to Zhengzhou University · CNShanghai Zhabei District Shibei Hospital · CN

Funding

Health System Independent Innovation Science Foundation of Shanghai Putuo District No.ptkwws201819Medical Science and Technology project of Henan Province in 2019 No.LHGJ20190567National Natural Science Foundation of China 81972409
6 · The paper itself

Abstract

backgroundMetastasis is a crucial aspect of disease progression leading to death in patients with prostate cancer (PCa). However, its mechanism remains unclear. We aimed to explore the mechanism of lymph node metastasis (LNM) by analyzing the heterogeneity of tumor microenvironment (TME) in PCa using scRNA-seq.

methodsA total of 32,766 cells were obtained from four PCa tissue samples for scRNA-seq, annotated, and grouped. InferCNV, GSVA, DEG functional enrichment analysis, trajectory analysis, intercellular network evaluation, and transcription factor analysis were carried out for each cell subgroup. Furthermore, validation experiments targeting luminal cell subgroups and CXCR4 + fibroblast subgroup were performed.

resultsThe results showed that only EEF2 + and FOLH1 + luminal subgroups were present in LNM, and they appeared at the initial stage of luminal cell differentiation, which were comfirmed by verification experiments. The MYC pathway was enriched in the EEF2 + and FOLH1 + luminal subgroups, and MYC was associated with PCa LNM. Moreover, MYC did not only promote the progression of PCa, but also led to immunosuppression in TME by regulating PDL1 and CD47. The proportion of CD8 + T cells in TME and among NK cells and monocytes was lower in LNM than in the primary lesion, while the opposite was true for Th and Treg cells. Furthermore, these immune cells in TME underwent transcriptional reprogramming, including CD8 + T subgroups of CCR7 + and IL7R+, as well as M2-like monocyte subgroups expressing tumor-associated signature genes, like CCR7, SGKI, and RPL31. Furthermore, STEAP4+, ADGRF5 + and CXCR4+, and SRGNC + fibroblast subgroups were closely related to tumor progression, tumor metabolism, and immunosuppression, indicating their contributions in PCa metastasis. Meanwhile, The presence of CXCR4 + Fibroblasts in PCa was confirmed by polychromatic immunofluorescence.

conclusionsThe significant heterogeneity of luminal, immune, and interstitial cells in PCa LNM may not only directly contribute to tumor progression, but also indirectly result in TME immunosuppression, which may be the cause of metastasis in PCa and in which MYC played an role.

Indexed as

ImmunosuppressionMetastasisProstate CancerSingle-cell RNA sequencingTumor Microenvironment

Identifiers

PMID37221625
PMCPMC10204220
OpenAlexW4377940974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.